Top

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous ribonucleoprotein K (hnRNPK), appears to lead to cancer development when overexpressed and may lead to new methods for assessing patients and to the development of new lymphoma treatment approaches.

Findings from the study, led by Sean Post, Ph.D., associate professor of Leukemia at MD Anderson...

Sean Post, Ph.D.

BY Ron Gilmore

Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma...

BY Scott Merville

Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...

BY Sarah Bronson

Two new clinical trials at MD Anderson are taking aim at mantle cell lymphoma – a rare form of non-Hodgkin’s lymphoma.

Most mantle cell lymphoma trials test new treatments on patients with relapsed disease, but MD Anderson’s trials are focusing on patients who are newly diagnosed.

“The first therapy is the most important,” said Michael Wang, M.D., professor of Lymphoma and Myeloma and the trial’s principal investigator....

BY Scott Merville

MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...

BY Clayton Boldt, Ph.D.

The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...

BY Ron Gilmore

Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T...